telmisartan has been researched along with Dyslipidemia in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (7.69) | 29.6817 |
| 2010's | 10 (76.92) | 24.3611 |
| 2020's | 2 (15.38) | 2.80 |
| Authors | Studies |
|---|---|
| Ahn, JC; Chae, IH; Cho, EJ; Cho, JM; Cho, Y; Choi, SY; Han, KH; Hong, SJ; Hong, SP; Hwang, J; Hyon, MS; Jin, X; Kim, H; Kim, HS; Kim, JH; Kim, MH; Kim, PJ; Kim, WS; Kwon, K; Lee, H; Lee, HC; Lee, JH; Lee, K; Lee, SH; Park, CG; Rhee, MY; Seo, JS; Shin, JH; Sung, JH; Sung, KC; Yoo, BS | 1 |
| Choi, J; Ihm, SH; Kim, JY; Kwon, SU; Lee, HY; Park, SH; Park, SW; Sung, KC; Yoon, CH | 1 |
| Bae, JH; Baek, SH; Cho, J; Choi, YJ; Doh, JH; Han, JK; Han, KH; Hong, KS; Hyon, MS; Ihm, SH; Jeong, JO; Kim, H; Kim, HS; Kim, MH; Kim, SH; Kim, SJ; Lee, BK; Oh, GC; Rhee, MY; Rhew, JY; Shin, ES; Sung, JH; Yoo, BS | 1 |
| Ahn, Y; Chang, K; Cho, JM; Hong, SJ; Hyon, MS; Jeong, HS; Kang, WC; Kim, HS; Lee, JH; Pyun, WB | 1 |
| Jing, DQ; Liu, M; Lu, JM; Mu, YM; Pan, CY; Yin, SN | 1 |
| DiNicolantonio, JJ; Elisaf, MS; Liberopoulos, EN; Rizos, CV; Tellis, K; Tselepis, AD | 1 |
| Chen, X; Deng, S; Fang, D; Ma, Y; Nie, Y; Song, X; Xie, Y; Xinyue, L; Xu, C; Zhang, Z | 1 |
| Chen, PP; Hu, ZB; Liu, BC; Liu, L; Lu, J; Ma, KL; Ruan, XZ; Wang, GH; Wen, Y; Wu, Y; Zhang, Y | 1 |
| He, WK; He, ZC; Lai, Q; Liang, LY; Lu, DF; Luo, JD; Pan, XD; Wang, W; Wen, YH; Xiao, AY; Zeng, ZH | 1 |
| Goyal, BR; Goyal, RK; Mehta, AA; Parmar, K | 1 |
| Goyal, BR; Mehta, AA | 1 |
| Arao, T; Mori, H; Nishida, K; Okada, Y; Tanaka, Y | 1 |
| Aranda, FJ; Aranda, P; Frutos, MA; López de Novales, E; López, V; Ruilope, LM; Segura, J | 1 |
8 trial(s) available for telmisartan and Dyslipidemia
| Article | Year |
|---|---|
Efficacy and safety of co-administered telmisartan/amlodipine and rosuvastatin in subjects with hypertension and dyslipidemia.
Topics: Aged; Amlodipine; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Dyslipidemias; Female; Humans; Hypertension; Male; Middle Aged; Rosuvastatin Calcium; Telmisartan | 2020 |
Central blood pressure lowering effect of telmisartan-rosuvastatin single-pill combination in hypertensive patients combined with dyslipidemia: A pilot study.
Topics: Ankle Brachial Index; Antihypertensive Agents; Benzoates; Blood Pressure; COVID-19; Drug Combinations; Dyslipidemias; Humans; Hypertension; Pandemics; Pilot Projects; Prospective Studies; Pulse Wave Analysis; Rosuvastatin Calcium; SARS-CoV-2; Telmisartan | 2021 |
Efficacy and Safety of Fixed-dose Combination Therapy With Telmisartan and Rosuvastatin in Korean Patients With Hypertension and Dyslipidemia: TELSTA-YU (TELmisartan-rosuvaSTAtin from YUhan), a Multicenter, Randomized, 4-arm, Double-blind, Placebo-control
Topics: Aged; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Drug Combinations; Dyslipidemias; Female; Humans; Hypertension; Male; Middle Aged; Rosuvastatin Calcium; Telmisartan | 2018 |
Efficacy and Safety of Triple Therapy With Telmisartan, Amlodipine, and Rosuvastatin in Patients With Dyslipidemia and Hypertension: The Jeil Telmisartan, Amlodipine, and Rosuvastatin Randomized Clinical Trial.
Topics: Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Blood Pressure; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Humans; Hypertension; Male; Middle Aged; Republic of Korea; Rosuvastatin Calcium; Telmisartan | 2019 |
Combining rosuvastatin with angiotensin-receptor blockers of different PPARγ-activating capacity: effects on high-density lipoprotein subfractions and associated enzymes.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Aged; Angiotensin II Type 1 Receptor Blockers; Aryldialkylphosphatase; Benzimidazoles; Benzoates; Biomarkers; Biphenyl Compounds; Cholesterol, HDL; Drug Therapy, Combination; Dyslipidemias; Female; Fluorobenzenes; Greece; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Imidazoles; Irbesartan; Lipoproteins, HDL; Male; Middle Aged; PPAR gamma; Prediabetic State; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Telmisartan; Tetrazoles; Treatment Outcome | 2015 |
The effects of simvastatin on left ventricular hypertrophy and left ventricular function in patients with essential hypertension.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Blood Pressure; Drug Therapy, Combination; Dyslipidemias; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Hypertrophy, Left Ventricular; Lipids; Male; Simvastatin; Telmisartan; Treatment Outcome; Ultrasonography; Ventricular Function, Left | 2011 |
Antihypertensive and metabolic effects of high-dose olmesartan and telmisartan in type 2 diabetes patients with hypertension.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Benzimidazoles; Benzoates; C-Reactive Protein; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug Resistance; Dyslipidemias; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Hypoglycemic Agents; Imidazoles; Insulin Resistance; Male; Middle Aged; Telmisartan; Tetrazoles | 2013 |
Long-term renoprotective effects of standard versus high doses of telmisartan in hypertensive nondiabetic nephropathies.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Creatinine; Dose-Response Relationship, Drug; Dyslipidemias; Female; Follow-Up Studies; Humans; Hypertension; Kidney Diseases; Kidney Failure, Chronic; Male; Middle Aged; Proteinuria; Renin-Angiotensin System; Telmisartan; Treatment Outcome | 2005 |
5 other study(ies) available for telmisartan and Dyslipidemia
| Article | Year |
|---|---|
Telmisartan increases lipoprotein lipase expression via peroxisome proliferator-activated receptor-alpha in HepG2 cells.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Dyslipidemias; Gene Expression; Hep G2 Cells; Humans; Lipoprotein Lipase; Myoblasts; PPAR alpha; RNA, Messenger; Telmisartan | 2014 |
Effect of telmisartan on the therapeutic efficacy of pitavastatin in high-fat diet induced dyslipidemic guinea pigs.
Topics: Adipocytes; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; Body Weight; Diet, High-Fat; Drug Interactions; Dyslipidemias; Gene Expression Regulation; Guinea Pigs; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Liver; Male; Quinolines; Telmisartan | 2015 |
Lipid disorder and intrahepatic renin-angiotensin system activation synergistically contribute to non-alcoholic fatty liver disease.
Topics: Angiotensin II; Animals; Benzimidazoles; Benzoates; Cholesterol; Diet, High-Fat; Dyslipidemias; Extracellular Matrix; Hep G2 Cells; Humans; Intracellular Signaling Peptides and Proteins; Lipid Metabolism; Male; Membrane Proteins; Mice; Mice, Inbred C57BL; Mice, Knockout; Non-alcoholic Fatty Liver Disease; Receptor, Angiotensin, Type 1; Receptors, LDL; Renin-Angiotensin System; Signal Transduction; Sterol Regulatory Element Binding Protein 2; Telmisartan | 2016 |
Beneficial role of telmisartan on cardiovascular complications associated with STZ-induced type 2 diabetes in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Benzimidazoles; Benzoates; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Male; Oxidative Stress; Rats; Rats, Sprague-Dawley; Streptozocin; Telmisartan | 2011 |
Beneficial role of spironolactone, telmisartan and their combination on isoproterenol-induced cardiac hypertrophy.
Topics: Adrenergic beta-Agonists; Algorithms; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Benzoates; C-Reactive Protein; Cardiomegaly; Creatine Kinase, MB Form; Disease Models, Animal; Diuretics; Drug Therapy, Combination; Dyslipidemias; Hemodynamics; Injections, Intraperitoneal; Isoproterenol; Rats; Rats, Wistar; Spironolactone; Telmisartan; Treatment Outcome | 2012 |